Answer
Sunitinib malate inhibits multiple receptor tyrosine kinases involved in tumour growth, new blood vessel formation and metastatic progression—PDGFRα/β, VEGFR1/2/3, KIT, FLT3, CSF-1R and RET—and its primary metabolite has similar potency in biochemical and cellular assays.
Sources for this answer
- SUTENT 50mg Hard CapsulesPfizer Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 52Document updated
Sources checked